John Duncan Higgons - Net Worth and Insider Trading

John Duncan Higgons Net Worth

The estimated net worth of John Duncan Higgons is at least $4 Million dollars as of 2024-11-13. John Duncan Higgons is the COO of Agios Pharmaceuticals Inc and owns about 61,835 shares of Agios Pharmaceuticals Inc (AGIO) stock worth over $4 Million. John Duncan Higgons is also the Director of Jounce Therapeutics Inc and owns about 9,713 shares of Jounce Therapeutics Inc (JNCE) stock worth over $18,260. Details can be seen in John Duncan Higgons's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that John Duncan Higgons has not made any transactions after 2021-04-15 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

GuruFocus Premium Membership
30 Years of Financial Data on One Screen
Unlimited Filters in All-in-One Stock Screener
Exclusive Earnings Calls & Stock Analysis
Customizable Stock Dashboard
Real-Time Insider Trading Alerts
8,000+ Institutional Investors’ 13F Holdings
Excel & Google Sheets Integration
Downloadable Data
Quick Customer Support
And Much More...

Transaction Summary of John Duncan Higgons

To

John Duncan Higgons Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, John Duncan Higgons owns 2 companies in total, including Jounce Therapeutics Inc (JNCE) , and Agios Pharmaceuticals Inc (AGIO) .

Click here to see the complete history of John Duncan Higgons’s form 4 insider trades.

Insider Ownership Summary of John Duncan Higgons

Ticker Comapny Transaction Date Type of Owner
JNCE Jounce Therapeutics Inc 2021-04-15 director
AGIO Agios Pharmaceuticals Inc 2015-12-15 10 percent owner & Chief Operating Officer

John Duncan Higgons Latest Holdings Summary

John Duncan Higgons currently owns a total of 2 stocks. Among these stocks, John Duncan Higgons owns 61,835 shares of Agios Pharmaceuticals Inc (AGIO) as of December 15, 2015, with a value of $4 Million and a weighting of 99.5%. John Duncan Higgons also owns 9,713 shares of Jounce Therapeutics Inc (JNCE) as of April 15, 2021, with a value of $18,260 and a weighting of 0.5%.

Latest Holdings of John Duncan Higgons

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
AGIO Agios Pharmaceuticals Inc 2015-12-15 61,835 59.02 3,649,502
JNCE Jounce Therapeutics Inc 2021-04-15 9,713 1.88 18,260

Holding Weightings of John Duncan Higgons


John Duncan Higgons Form 4 Trading Tracker

According to the SEC Form 4 filings, John Duncan Higgons has made a total of 0 transactions in Agios Pharmaceuticals Inc (AGIO) over the past 5 years. The most-recent trade in Agios Pharmaceuticals Inc is the sale of 20,000 shares on December 15, 2015, which brought John Duncan Higgons around $1 Million.

According to the SEC Form 4 filings, John Duncan Higgons has made a total of 5 transactions in Jounce Therapeutics Inc (JNCE) over the past 5 years, including 0 buys and 5 sells. The most-recent trade in Jounce Therapeutics Inc is the sale of 200 shares on April 15, 2021, which brought John Duncan Higgons around $2,000.

Insider Trading History of John Duncan Higgons

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

John Duncan Higgons Trading Performance

GuruFocus tracks the stock performance after each of John Duncan Higgons's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by John Duncan Higgons is 66.53%. GuruFocus also compares John Duncan Higgons's trading performance to market benchmark return within the same time period. The performance of stocks bought by John Duncan Higgons within 3 months outperforms 1 times out of 1 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how John Duncan Higgons's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of John Duncan Higgons

Average Return

LIMIT
Average return per transaction

Outperforming Transactions

LIMIT
1 out of 1 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 24.34 LIMIT LIMIT LIMIT LIMIT LIMIT
Relative Return to S&P 500(%) 19.23 LIMIT LIMIT LIMIT LIMIT LIMIT

John Duncan Higgons Ownership Network

Ownership Network List of John Duncan Higgons

No Data

Ownership Network Relation of John Duncan Higgons

Insider Network Chart

John Duncan Higgons Owned Company Details

What does Jounce Therapeutics Inc do?

Who are the key executives at Jounce Therapeutics Inc?

John Duncan Higgons is the director of Jounce Therapeutics Inc. Other key executives at Jounce Therapeutics Inc include 10 percent owner Concentra Merger Sub, Inc. , 10 percent owner Concentra Biosciences, Llc , and director & CEO and President Richard /ca/ Murray .

Jounce Therapeutics Inc (JNCE) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Jounce Therapeutics Inc (JNCE) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Jounce Therapeutics Inc (JNCE) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Jounce Therapeutics Inc (JNCE)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Jounce Therapeutics Inc Insider Transactions

No Available Data

John Duncan Higgons Mailing Address

Above is the net worth, insider trading, and ownership report for John Duncan Higgons. You might contact John Duncan Higgons via mailing address: C/o Agios Pharmaceuticals, Inc., 38 Sidney Street, 2nd Floor, Cambridge Ma 02139.